Story of this company from the day it was formed!
Tomorrow never comes!
Printable View
NZX being ‘charitable’ in only fining them $25k plus costs …might have gone broke if more
http://nzx-prod-s7fsd7f98s.s3-websit...249/410407.pdf
CEO gone
https://www.nzx.com/announcements/426689
Truscreen Group Limited (NZX/ASX:TRU) announces that for personal reasons, CEO, Dr. Beata Edling has resigned effective immediately and will assist in the transition to an interim CEO in the coming weeks. Beata has personal commitments to family in Poland and will be available to assist TruScreen on a consulting basis to further the business in Poland and central Europe.
https://www.nzx.com/announcements/432065
TruScreen FY24 Preliminary Results
(all numbers in New Zealand Dollars)
Highlights
• SUS unit sales up 25% on prior year and device sales to distributors in line with prior year
• Major breakthrough in China with two peak organisations including TruScreen in their cervical cancer screening guidelines - China Obstetrics and Gynecology Association (COGA) Blue Paper and endorsement from the Chinese Society for Colposcopy and Cervical Pathology (CSCCP)
• Commercial operations commenced in Saudi Arabia and further progress in Zimbabwe
• In Vietnam TruScreen achieved inclusion on the Vietnamese Ministry Of Health (MOH) approved Technical List
• In Mexico the national regulator, Cofepris approved TruScreen access to the public health sector
• Developing new market opportunities in Uzbekistan, Indonesia, and Africa
• Successful capital raise and appointment of new Chief Executive Officer
• Improved Operations metrics.
o Sales up by 27%, led by SUS consumable sales increase of 25%.
o Operating loss reduced by 15%
o Cash outflow reduced by 9%
Conclusion
TS represents a reliable, practical screening tool for cervical neoplasms without the need for cervical samples, laboratory
equipment, or trained staff. Although the doctors did the examination in our study, nurses can also be trained and get
involved in screening programs to perform TS examinations independently. Our study showed that the tool provided real-
time and accurate screening results, making it suitable for quick screening of at-risk women or in low-resource settings.
Additionally, it could potentially prompt the see-and-treat protocol as more evidence emerges in favor of such an
approach.
Our results can provide an evidence-based approach for policymakers when selecting the optimal cervical cancer
screening strategy in countries without an established national screening program. However, additional research is still
needed to conrm the clinical ecacy of TS in the Middle East population
Now an announcement to the market...
https://www.nzx.com/announcements/435576